Navigation Links
Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
Date:9/30/2013

SAN FRANCISCO, Sept. 30, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reported today that AstraZeneca announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist, which has been specifically designed for the treatment of opioid-induced constipation (OIC) for adult patients 18 years and older, including patients with inadequate response to laxatives.

The MAA filing was based on comprehensive data from the core Phase III KODIAC programme, comprised of four clinical trials designed to investigate the safety and efficacy of naloxegol for the treatment of OIC. Two pivotal Phase III studies, KODIAC-04 (n=652) and KODIAC-05 (n=700), both 12-week, multicentre, randomised, double blind, placebo-controlled pivotal trials evaluated 12.5 mg and 25 mg doses of naloxegol, administered once-daily. KODIAC-07 was a 12-week safety extension of KODIAC-04, and KODIAC-08 (n= 534) was an open-label, randomised, 52-week, long-term safety trial.

Naloxegol has the potential to be the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for patients with OIC. Naloxegol was developed using Nektar's oral small molecule polymer conjugate technology.

Naloxegol is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics. Under the terms of the recently amended License Agreement, AstraZeneca will pay Nektar a $25 million milestone within five business days of acceptance of the MAA by the EMA.

NOTES TO EDITORS

About Opioid-Induced Constipation
OIC is a condition caused by prescription opioid pain medicines. Opioids bind to specific proteins called opioid receptors. When the opioids bind to certain opioi
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
2. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
3. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
4. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
5. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
6. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
10. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
11. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014  Edwards Lifesciences Corporation (NYSE: ... science of heart valves and hemodynamic monitoring, announced today ... 2014 to support a strong launch of Edwards Lifesciences ... and to improve the global communities where its employees ... global corporate giving will exceed $8 million, including more ...
(Date:11/21/2014)... 2014  The acceptance of two abstracts on ... Congress demonstrates continued interest in the Eclipse System, ... control. One of the abstracts, presented by Catherine ... of Urogynecology and Reconstructive Pelvic Surgery at the ... Best Written Abstract on Urogynecology/Pelvic Floor Disorders/Vaginal Surgery. ...
(Date:11/21/2014)... ATLANTA , Nov. 20, 2014   ... health management (PHM) for healthcare organizations, announced today ... the 2014 Intel Innovation Award .  Sponsored ... the award, in its fourth year, recognizes companies ... health and healthcare delivery processes. ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... House passed H.R. 5651, its version of the Prescription ... to mitigate drug shortages, most notably mandating an early ... professional society concerned with the causes and treatment of ... in blood cancers such as leukemia, lymphoma, and myeloma, ...
... U.S. Food and Drug Administration (FDA) has approved ... (NYSE: BSX ) INCEPTA™, ENERGEN™, PUNCTUA™, ... cardiac resynchronization therapy defibrillators (CRT-Ds), to reflect increased ... are based on data submitted to the FDA ...
Cached Medicine Technology:American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA) 2Boston Scientific Increases Longevity Projections for Its U.S. Defibrillators 2Boston Scientific Increases Longevity Projections for Its U.S. Defibrillators 3Boston Scientific Increases Longevity Projections for Its U.S. Defibrillators 4
(Date:11/22/2014)... classic black prom dress will never go out of fashion. ... its new items of black prom gowns . Now ... discount, up to 70% off. People throughout the world can ... dresses, made with the best materials, can make wearers feel ... the company provides these beautiful outfits in a huge range ...
(Date:11/22/2014)... York, NY (PRWEB) November 22, 2014 ... Therapeutics Goods Administration (TGA) approved it for use ... was approved and listed within the Therapeutic Goods ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione will ... a biotech specialist that sources and imports fine ...
(Date:11/22/2014)... 22, 2014 Nocturia is defined ... complaint that the individual has to wake at ... report “Nocturia – Pipeline Review, H2 2014” provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
(Date:11/22/2014)... 22, 2014 (HealthDay News) -- The wide variety and ... a threat for people with food allergies, an expert ... so many types of food allergies that it can ... holidays," Dr. Guha Krishnaswamy, director of allergy and clinical ... a hospital news release. "If you know you ...
(Date:11/22/2014)... Hastings and Hastings, a discount accident ... providing clients with the option of leaving an online ... flexible, intuitive and easy to navigate website that has ... Google + allows clients to research the Hastings and ... informed decision when retaining an attorney. Those who have ...
Breaking Medicine News(10 mins):Health News:New Black Prom Dresses from BellasDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3
... Neuroimagingis it voodoo, new phrenology, or scientific breakthrough? ... this special section on fMRI in Perspectives ... New Phrenology, or Scientific Breakthrough? Introduction to Special ... Ed Diener In response to the widespread ...
... -- If you have trouble understanding people with regional ... understand what they,re saying, a new study suggests. ... sentences spoken in an unfamiliar accent. But before they ... on how to respond to the sentences. Some were ...
... Reporter , WEDNESDAY, Dec. 8 (HealthDay News) -- Sudden infant death ... mysterious and terrifying killer of newborns. But medical researchers now ... die of SIDS, an advance that could save hundreds of ... of SIDS tend to have significantly lower amounts of serotonin than ...
... Dec. 8 (HealthDay News) -- A new U.S. study ... severely in black children than white children. The ... said the researchers at the University of Alabama at ... black and 22 white children with MS, a chronic ...
... Patients who have complications after colorectal cancer surgery ... is clearly recommended for their diagnosis, a new study ... In addition, patients with complications were more than ... more than 120 days after diagnosis or two months ...
... an irresistible force, has proven 99 percent effective in ... causing $2 billion in annual loses to the cattle ... ACS, biweekly Journal of Agricultural and Food Chemistry ... flies not only inflict painful bites, but also transmit ...
Cached Medicine News:Health News:fMRI special section of Perspectives on Psychological Science 2Health News:fMRI special section of Perspectives on Psychological Science 3Health News:Serotonin May Be the Key to SIDS 2Health News:Serotonin May Be the Key to SIDS 3Health News:Surgery complications linked to chemotherapy delay, U-M study finds 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: